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Abstract
Objective: This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to determine
the effect of alpha-lipoic acid (ALA) supplementation on the inflammatory markers among patients with metabolic
syndrome (MetS) and related disorders.
Methods: We searched the following databases until November 2017: PubMed, MEDLINE, EMBASE, Web of Science,
and Cochrane Central Register of Controlled Trials. Three reviewers independently assessed study eligibility, extracted
data, and evaluated risk of bias of included primary studies. Statistical heterogeneity was assessed using Cochran’s Q
test and I-square (I2) statistic. Data were pooled by using the random-effect model and standardized mean difference
(SMD) was considered as the summary effect size.
Results: Eighteen trials out of 912 potential citations were found to be eligible for our meta-analysis. The findings
indicated that ALA supplementation significantly decreased C-reactive protein (CRP) (SMD = − 1.52; 95% CI, − 2.25, − 0.
80; P < 0.001), interlokin-6 (IL-6) (SMD = − 1.96; 95% CI, − 2.60, − 1.32; P < 0.001), and tumor necrosis factor alpha levels
(TNF-α) (SMD = − 2.62; 95% CI, − 3.70, − 1.55; P < 0.001) in patients diagnosed with metabolic diseases.
Conclusion: In summary, the current meta-analysis demonstrated the promising impact of ALA administration on
decreasing inflammatory markers such as CRP, IL-6 and TNF-α among patients with MetS and related disorders.
Keywords: Alpha-lipoic acid, Inflammatory markers, Meta-analysis
Introduction
Increased pro-inflammatory markers and oxidative stress
occurs in adipose tissues are the two factors that may
play a key role in the incidence of metabolic-related co-
morbidities among patients with metabolic disorders [1].
Increased chronic inflammation is associated with
increased risk of metabolic disorders, including type 2
diabetes mellitus (T2DM) [2] and arteriosclerosis,
endothelial dysfunction, vascular calcification, increased
activity of metalloproteinases, oxidative damage, and
degradation of collagen [3–5]. It was reported that meta-
bolic syndrome (MetS) is associated with a 2-fold in-
creased risk of cardiovascular disease (CVD) over the
next 5 to 10 years [6]. Inflammatory cytokines including
interleukin-6 (IL-6) and tumor necrosis factor-alpha
(TNF-α) are usually produced by different cells including
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endothelial, immune and arterial smooth muscle cells in-
ducing the migration of additional immune cells into the
atherosclerotic lesion and the activation of the acute
phase C-reactive protein (CRP) in the liver [7, 8].
Increased levels of CRP are associated with increased
risk of CVD and diabetes [9, 10]. In addition to CRP,
other inflammatory biomarkers such as IL-6 and TNF-α
may be correlated with the development of CVD in dia-
betic patients [11].
Complementary therapies such as antioxidants supple-
mentation are recommended in patients with metabolic
abnormalities to improve their nutritional status and
boost their immune system [12]. Existing evidence has
proved the beneficial effects of several antioxidants sup-
plements including pentoxifylline [13] and lycopene [14]
on reducing inflammation. Available data regarding the
effects of alpha-lipoic acid (ALA) supplementation on
inflammatory markers are controversial. In a study by
Carbonelli et al. [15], obese Caucasian people showed
significant reduction in CRP and TNF-α concentrations
following ALA supplementation (800 mg/day) for
4 months. ALA supplementation (600–1000 mg/day)
during a period ranging from 2 wk. to 1 year in patients
with impaired glucose tolerance showed contradictory
results. Zhang et al. [16] demonstrated that ALA supple-
mentation decreased TNF-α and IL-6 while increased
adiponectin levels, however others did not observe any
beneficial effects of ALA on inflammatory markers [17, 18].
Discrepancies in these findings may be due to differences in
study design, characteristics of study populations, dosage of
ALA used and duration of the intervention.
We are aware of no systematic review or meta-ana-
lyses of randomized controlled trials (RCTs) evaluating
the effect of ALA supplementation on inflammatory
markers among patients with MetS and related disor-
ders. Thus, the current meta-analysis was performed to
summarize the available evidence regarding the effect of
ALA supplementation on inflammatory markers among
patients with MetS and related disorders.
Materials and methods
Search strategy and selection studies
We searched the following databases until November
2017: PubMed, MEDLINE, EMBASE, Web of Science,
and Cochrane Central Register of Controlled Trials.
Additionally, a manual search was conducted among the
references lists of all eligible articles and review studies
to identify potential articles that were not captured by
the electronic searches. Three authors (VO, MM and
MA) independently performed the literature search to
retrieve RCTs that have examined the association be-
tween ALA supplementation and the inflammatory
markers by using the following MeSH and text
keywords: patients [“Mets” OR “disorders related to
MetS” OR “diabetes” OR “T1DM” OR “T2DM” OR
“overweight” OR “obese” OR “chronic kidney disease
(CKD)” OR “hypertension” OR “high blood pressure”
OR “dyslipidemia” OR “CVD”], intervention (“alpha-li-
poic acid” OR “ALA” OR “α-lipoic acid” AND “supple-
mentation” OR “intake”), and outcomes [“CRP” OR
“IL-6” OR “TNF-α”]. Eligible studies were restricted to
those RCTs published in English language.
Inclusion and exclusion criteria
RCTs were selected using the following inclusion criteria:
being a placebo-controlled randomized trial (either parallel
or cross-over designs), human studies conducted in adults,
the target population was patients diagnosed with meta-
bolic diseases, and studies reported mean changes between
pre- and post-intervention CRP and/or IL-6 and/or TNF-α
following ALA supplementation for the intervention and
placebos groups. Other types of human studies (cross-sec-
tional, cohort studies), animal, in vitro studies, and review
papers were excluded. Case reports or cases series, and the
studies did not achieve the minimum quality assessment
score, those receiving any non-steroidal anti-inflammatory
drug or ALA supplements within the last month were also
excluded from the study.
Data extraction and quality assessment
Three authors (VO, MM, and MA) reviewed each trial
and extracted all related data, independently. The dis-
agreement among them was resolved by discussion with a
fourth author (ZA). The quality of the included RCTs was
assessed using the Cochrane Collaboration risk of bias
tool based on the following information: randomization
generation, allocation concealment, blinding of partici-
pants and outcome assessment, incomplete outcome data,
and selective outcome reporting, as well as the other
sources of bias. The extracted data included: first author,
publication year, demographical variables, study design,
sample size, dose of intervention, duration of study, type
of intervention, type of disease, the mean and standard de-
viation (SD) for CRP, IL-6, and TNF-α.
Data synthesis and statistical analysis
We preformed a comprehensive electronic and manual
search to avoid publication bias. Additionally, Egger’s re-
gression test was used to assess publication bias statisti-
cally [19]. Statistical heterogeneity was assessed using
Cochran’s Q and I-square (I2) tests [20]. I2 greater than
50% or P < 0.05 was considered as significant heterogen-
eity. We estimated the difference between intervention
(ALA supplementation) and placebo group by calculat-
ing the standardized mean difference (SMD) with 95%
confidence interval (CI) using STATA software version
12.0 (Stata Corp., College Station, TX) and RevMan
V.5.3 software (Cochrane Collaboration, Oxford, UK).
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Since the indications could effect on pooled SMD were
different between included studies, we used random-ef-
fects models to perform meta-analyses. Subgroup and
sensitivity analyses were conducted to assess the source
of heterogeneity and to explore the contribution of each
study to the reliability of the pooled mean difference,
respectively. P-values < 0.05 were considered as statis-
tically significant.
Results
The process of the step by step study selection has shown
in Additional file 1. Overall, 18 trials out of 912 potential
citations were found to be eligible for this meta-analysis.
Seven studies were RCTs design, and eleven were ran-
domized, double-blind, placebo-controlled trials. Eleven
trials have assessed the effects of ALA supplementation
on CRP [21–31], eleven on IL-6 [16, 22–25, 30–35], and
nine on TNF-α levels [16, 22, 24, 25, 28, 32, 33, 36, 37].
Intervention duration among included studies varied from
2 weeks to 12 months. The dosage of ALA supplements
ranged from 300 to 600 (mg/day). Location of studies in-
cluded; four studies in Italy [25, 28, 29, 33], three in Iran
[23, 27, 37], three in China [16, 21, 22], two in Egypt
[35, 36], one in Spain [30], one in Romania [32], two
in United States [31, 34], one in Korea [26], and one
in New Zealand [24]. Details of the included studies
are summarized in Table 1. The quality of included
trials is presented in Additional file 2.
Main outcomes
The results of current meta-analysis showed that ALA
supplementation significantly decreased CRP (SMD = −
1.52; 95% CI, − 2.25, − 0.80; P < 0.001; I2: 93.7), IL-6
(SMD = − 1.96; 95% CI, − 2.60, − 1.32; P < 0.001; I2: 90.6),
and TNF-α levels (SMD = − 2.62; 95% CI, − 3.70, − 1.55;
P < 0.001; I2: 94.3) in patients with MetS and related
disorders (Table 2 and Fig. 1).
We also performed subgroup analyses according to
geographic area (Asia, European, USA, Oceania, and Af-
rica), dosage of ALA supplements (> 600 vs. ≤600 mg/
day), co-administration with other nutrients (ALA vs.
ALA plus other nutrients), duration of the intervention
(≥8 vs. < 8 weeks), and type of diseases (diabetic, ESRD
vs. other diseases). We found that heterogeneity may de-
crease by duration of the intervention (< 8 weeks = I2:
89.9 and ≥ 8 weeks = I2:85.1 vs. overall I2:90.6%) and type
of diseases (diabetic = I2: 75.1 and other = I2:89.5 vs.
overall I2:90.6%) for IL-6 and type of diseases (diabetic =
I2: 92.8 and other = I2:94.0 vs. overall I2:94.3%) for
TNF-α levels (< 8 weeks = I2: 88.2 and ≥ 8 weeks = I2:92.1
vs. overall I2:94.5%). The detailed of subgroup analysis
are presented in Table 3.
In sensitivity analysis, we found no significant differ-
ence between the pre- and post-sensitivity analysis for
all inflammatory markers. The smallest and greatest
pooled SMDs in the sensitivity analyses for the level of
inflammatory markers are shown in Additional file 3.
Egger’s regression tests showed no significant publica-
tion bias for the effects of ALA on CRP (B = − 11.35,
P = 0.01). We found publication bias for IL-6 (B = −
6.88, P = 0.00) and TNF-α (B = − 7.28, P = 0.01), so we
non parametric method was applied (Duval and
Tweedie) to estimate the findings of censored studies.
Findings showed that the summary of effect size for
IL-6 and TNF-α did not significantly changed be-
tween before and after inclusion of censored studies
for CRP (SMD = − 1.69; 95% CI, − 2.48, − 0.90), IL-6
(SMD = − 1.96; 95% CI, − 2.60, − 1.32), and TNF-α
(SMD = − 2.62; 95% CI, − 3.70, − 1.55).
Discussion
This systematic review and meta-analysis assessed the ef-
fect of ALA supplementation on inflammatory markers in
patients with MetS and related disorders. Our findings
Table 2 Estimation of the standardized difference means of related indictors with CI 95% between the intervention and placebo
groups
Variables Number
of study
Standardized mean
difference
CI 95% Heterogeneity
I2 (%) Q P-value
CRP Intervention group (after vs. before) 11 −0.88 −1.55, − 0.21 92.4 130.85 < 0.001
Placebo group (after vs. before) 11 −0.29 − 0.67, 0.09 80.3 50.87 < 0.001
Change intervention group vs. placebo group 13 −1.52 −2.25, −0.80 93.7 191.17 < 0.001
IL-6 Intervention group (after vs. before) 13 −0.99 −1.48, − 0.51 85.0 79.92 < 0.001
Placebo group (after vs. before) 13 0.03 −0.16, 0.22 17.8 14.59 0.264
Change intervention group vs. placebo group 15 −1.96 −2.60, − 1.32 90.6 149.58 < 0.001
TNF-α Intervention group (after vs. before) 10 −1.41 −2.03, −0.79 87.0 69.13 < 0.001
Placebo group (after vs. before) 10 −0.33 − 0.72, 0.05 71.4 31.50 < 0.001
Change intervention group vs. placebo group 10 −2.62 −3.70, −1.55 94.3 157.51 < 0.001
IL-6 interlokin-6, CRP C-reactive protein, TNF-α tumor necrosis factor alpha
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ab
c
Fig. 1 a-c Meta-analysis glycemic control standardized mean differences estimates for (a) high-sensitivity C-reactive protein, (b) for interlokin-6,
and (c) for tumor necrosis factor alpha in alpha-lipoic acid supplements and placebo groups (CI = 95%)
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supported the beneficial impact of ALA administration on
lowering inflammatory markers in patients suffering from
metabolic syndrome and related disorders.
Few studies have reported the beneficial effects of anti-
oxidant supplementation on inflammatory cytokines. In
a meta-analysis conducted by Ju et al. [38], selenium
supplementation significantly decreased serum CRP levels
in patients with coronary heart disease, suggesting its po-
tential impact on reducing inflammation in chronic condi-
tions. In addition, supplementation with vitamin E in the
form of either α-tocopherol or γ-tocopherol resulted in a
significant reduction in CRP concentrations [39]. Available
Table 3 The assess of association between alpha-lipoic acid supplementation on inflammatory markers based on subgroup analysis
Variables Number of SMD
included
Subgroups Pooled OR
(random effect)
95% CI I2 (%) overall I2(%)
CRP Geographic area 6 Asia −1.20 −2.02, − 0.38 90.8 93.7
5 European −2.52 −4.26, −0.78 94.8
1 USA −0.46 − 0.98, 0.07 –
1 Oceania 0.05 −0.41, 0.51 –
Dosage of ALA (mg/day) 4 < 600 −1.29 −2.16, −0.42 81.4
9 ≥600 −1.64 −2.61, −0.66 95.4
Type of intervention 9 ALA −1.63 −2.67, −0.58 95.3
4 ALA plus other nutrients −1.30 −2.10, −0.50 85.0
Duration of study (week) 10 ≥8 −1.50 −2.35, −0.65 94.4
3 < 8 −1.63 −2.93, −0.32 88.6
Type of diseases 3 Diabetic −1.63 −2.93, −0.32 88.6
10 Other −1.50 −2.35, −0.65 94.4
IL-6 Geographic area 4 Asia −2.18 −3.34, −1.02 88.7 90.6
6 European −1.75 −2.71, −0.78 87.4
3 USA −4.10 −7.68, −0.52 96.3
1 Oceania −0.26 −0.72, 0.20 –
1 Africa −0.57 −1.17, 0.03 –
Dosage of ALA (mg/day) 5 < 600 −3.59 −5.50, −1.68 94.8
10 ≥600 −1.22 − 1.70, −0.74 78.4
Type of intervention 8 ALA −2.00 −2.88, −1.11 90.9
7 ALA plus other nutrients −1.98 −3.01, −0.95 91.7
Duration of study (week) 8 ≥8 −1.07 − 1.62, −0.52 85.1
7 < 8 −3.30 −4.61, −1.99 89.9
Type of diseases 2 Diabetic −3.40 −5.13, −1.66 75.1
13 Other −1.72 −2.35, − 1.09 89.5
TNF-α Geographic area 3 Asia −2.44 −4.67, −0.21 95.9 94.3
5 European −2.63 −3.87, −1.39 87.2
1 Oceania −0.34 − 0.80, 0.12 –
1 Africa −6.35 −8.16, −4.54 –
Dosage of ALA (mg/day) 1 < 600 −2.14 −2.77, −1.51 –
9 ≥600 −2.71 −3.94, − 1.48 94.7
Type of intervention 6 ALA −2.56 −4.08, −1.03 95.8
4 ALA plus other nutrients −2.73 −4.26, −1.20 89.3
Duration of study (week) 5 ≥8 −2.78 −4.57, −0.99 96.8
5 < 8 −2.40 −3.46, −1.33 80.2
Type of diseases 3 Diabetic −4.68 −7.82, −1.55 92.8
7 Other −1.89 −3.04, −0.73 94.0
ESRD end-stage renal disease, IL-6 interlokin-6, CRP C-reactive protein, TNF-α tumor necrosis factor alpha
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information regarding the effects of ALA supplementation
on inflammatory cytokines is inconclusive. ALA supple-
mentation for 12 months significantly decreased serum
levels of common markers of inflammation in ablated pa-
tients [25]. Furthermore, dietary supplementation with
ALA for 10 weeks significantly improved systemic inflam-
mation and cardiovascular disease-related risk factors in
healthy overweight women [30]. However, no benefits of
resveratrol supplementation were reported on cardiovascu-
lar risk factors in the meta-analysis conducted by Sahebkar
et al. [40]. In another study, taking ALA supplements for
8 weeks did not affect IL-8 and TNF-α levels in
hemodialysis patients [37]. Increased inflammatory markers,
especially TNF-α, might promote insulin resistance, and
alter expression of cytokines in adipose tissues which is con-
sidered an important link between MetS and insulin resist-
ance [41]. In addition, high levels of inflammatory markers
in diabetic patients and those suffering from diabetic ne-
phropathy are positively correlated with the severity of albu-
minuria [42]. Local inflammation plays also an important
role in the development of diabetic retinopathy [43].
ALA intake may reduce inflammatory markers
through scavenging free radicals, down-regulating
pro-inflammatory redox-sensitive signal transduction
processes including nuclear factor kappa B translocation,
leading to lower release of other free radicals and cyto-
toxic cytokines [44, 45]. Moreover, ALA administration
improves cellular antioxidant capacity and phases 2 en-
zymes such as catalase, reduced glutathione, glutathione
reductase, and glutathione-S-transferase [46]. ALA can
also inhibit the activation of serine kinases including
IKKβ to suppress inflammatory cytokines [47]. Zhang et
al. [48] mentioned to ALA potential to inhibit
TNF-α-induced I kappa B kinase activation. It is specu-
lated that the ALA treatment effects might be influenced
by its baseline values and improved blood levels over time.
In the current meta-analysis it was not possible to con-
sider the effect of baseline ALA values in determining the
impact of it on inflammatory markers. Furthermore, dif-
ferent geographical latitudes where study conducted might
further complicate the effect of baseline ALA values.
Overall, on top of those explained above, different study
designs, sample size, different dosages of ALA used along
with characteristics of study participants might explain
the discrepancies among different studies.
There are several strengths for this study. Higher
numbers of studies included in this analysis and longer
period of supplementation in included trials have added
to the value of this meta-analysis. All included studies
were placebo-controlled randomized trials with accept-
able methodological quality and the least probable
chance of bias. Further, we relied on independent judg-
ment in which different reviewers independently per-
formed the systematic review process.
The current meta-analysis had a few limitations. There
were few eligible RCTs, and most of them had a modest
number of participants. Various doses of ALA were ad-
ministered for intervention in the included studies. We
were unable to evaluate the dose response association
between supplementation dose and inflammatory
markers due to the low number of studies included. In
addition, we did not evaluate the residual confounding
and bias of each study that could not be addressed
through pooling. Considerable heterogeneity across
studies made our findings complicated to interpret the
main outcomes. Thus, evaluation of heterogeneity is a
crucial part of any meta-analysis.
Conclusions
Overall, the current meta-analysis supported the benefi-
cial impacts of ALA administration on decreasing in-
flammatory markers such as CRP, IL-6 and TNF-α
among patients with MetS and related disorders.
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